Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Benton

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Hematological Oncology|August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndromeChristopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Cancer|June 1, 2016
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesGevorg N Tamamyan, Hagop M Kantarjian, Jing Ning, et al.
American Journal of Hematology|July 28, 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-RChristopher B Benton, Maliha Khan, David Sallman, et al.
The Lancet. Haematology|August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialTapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.
American Journal of Hematology|April 10, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk diseaseAndrés E Quesada, Mark J Routbort, Courtney D DiNardo, et al.
Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Hematological Oncology|August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndromeChristopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Cancer|June 1, 2016
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomesGevorg N Tamamyan, Hagop M Kantarjian, Jing Ning, et al.
American Journal of Hematology|July 28, 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-RChristopher B Benton, Maliha Khan, David Sallman, et al.
The Lancet. Haematology|August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialTapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.
American Journal of Hematology|April 10, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk diseaseAndrés E Quesada, Mark J Routbort, Courtney D DiNardo, et al.
Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Pageof 7